We previously showed that quercetin (3,3',4',5,7 pentahydroxyflavone) inhibits in a dose-dependent manner the growth of acute leukemias and is able to enhance the antiproliferative activity of cytosine arabinoside. We show here that quercetin inhibits the clonogenic activity of 20 of 22 acute leukemias (AL; 4 MI-AML, 3 MS-AML, 2 MS-AML, 3 M4-AML, 3 M5-AML, and 7 ALL). In the present report, we show that the induction of transforming growth factor-PI (TGF-PI) in leukemic blasts is one of the growth-inhibitory mechanisms of quercetin in these cells. This observation was supported by the following data. (1) Quercetin-sensitive leukemic blasts, when treated with quercetin, secrete large F LAVONOIDS ARE A class of natural substances widely distributed in the plant kingdom' that display a variety of biologic actions.' Recently, we and others have shown that the flavonoid quercetin and of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) primary leukemic blasts.' Moreover, we have shown that quercetin is able to inhibit the colony formation by AML and ALL progenitors.' Furthermore, quercetin enhances the antiproliferative activity of cytosine arabinoside on the leukemic cell line HL60 and on fresh AML and ALL progenitors,' likely by interacting with the so-called type I1 estrogen binding sites (type I1 EBS)." ' The term of transforming growth factor-p (TGF-P) indicates a family of structurally related proteins with powerful hematopoietic regulatory properties."' TGF-p I stimulates or inhibits the in vitro growth of normal myeloid pro-TGF-01 might selectively act as a negative regulator on early hematopoietic progenitors, sparing more committed Several studies showed the inhibitory effect of TGF-p1 on the growth of primary AML blasts in all samples tested but one."^"
We previously showed that quercetin (3,3',4',5,7 pentahydroxyflavone) inhibits in a dose-dependent manner the growth of acute leukemias and is able to enhance the antiproliferative activity of cytosine arabinoside. We show here that quercetin inhibits the clonogenic activity of 20 and of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) primary leukemic blasts.' Moreover, we have shown that quercetin is able to inhibit the colony formation by AML and ALL progenitors.' Furthermore, quercetin enhances the antiproliferative activity of cytosine arabinoside on the leukemic cell line HL60 and on fresh AML and ALL progenitors,' likely by interacting with the so-called type I1 estrogen binding sites (type I1 EBS)." ' The term of transforming growth factor-p (TGF-P) indicates a family of structurally related proteins with powerful hematopoietic regulatory properties."' TGF-p I stimulates or inhibits the in vitro growth of normal myeloid pro-TGF-01 might selectively act as a negative regulator on early hematopoietic progenitors, sparing more committed Several studies showed the inhibitory effect of TGF-p1 on the growth of primary AML blasts in all samples tested but one."^"
Because we have previously observed that quercetin inhibits the growth of ovarian cancer cell line by inducing the expression of TGF-P 1 ,2' we evaluated whether the modulation of TGF-PI production by quercetin could be a mechanism by which this flavonoid exerts its growth-inhibitory effect on AML and ALL blasts. 
MATERIALS AND METHODS
Isolation cf leukemic blasts rrnd clonogenic as.say. Fresh leukemic blasts were isolated from heparinized bone marrow aspirates obtained from 20 leukemic patients ( l 4 AML and 6 ALL) at diagnosis and from 2 patients in relapse ( I AML and I ALL). All samples were obtained after informed consent was obtained. Diagnoses were established according to the French-American-British recommendaafter cytologic examinations and cytochemical assays (peroxidase and naphtyl acetate esterase). Immunologic phenotype was defined in ALL patients. Aspirates diluted with Hank's Balanced Salt Solution (HBSS) were layered onto Ficoll-Hypaque density gradient ( I ,077 g/mL, pH 7.6,292 mOsm/L) and centrifuged at 400g for 30 minutes. Light-density mononuclear cells contained more than 70% blast cells. In AML and in non-T ALL, T lymphocytes were removed by rosetting with neuraminidase-treated sheep erythrocytes. After T-cell depletion, the percentage of blasts in the resulting cell population was greater than 90%, as assessed by morphologic, cytoenLymatic. and immunophenotypic analysis. Blasts were suspended at I X 10' cells/mL in Iscove's modified Dulbecco's medium (IMDM: Flow Laboratories, Irvine, UK) containing 0.9% methylcellulose (Sigma, St Louis, MO). 2
x lo-' mol/L 2-mercaptoethanol (Sigma), 20% heat-inactivated fetal calf serum (HI-FCS; Flow Labs), and 10% phytohemagglutinin (PHA)-leukocyte-conditioned medium, prepared according to the method of Aye ct al." Aliquots of 0.1 mL were plated in 96-microwell flat-bottom plates (Becton Dickinson, Lincoln Park. NJ). All plates were incubated at 37°C i n a fully humidified S% C02-9S% air atmosphere. Quercetin (Aldrich. Steinheim, Germany) was added at the indicated concentration at the start of cultures and then every 2 days from an absolute ethanol stock solution. Ethanol (vehicle) concentration never exceeded I % (vol/vol) in untreated and treated cultures. Each sample was cultured in quadruplicate. After 6 to 10 days, aggregates consisting of 10 o r more cells were counted as colony-forming unit-leukemic (CFU-L).
Result are expressed as the number of colonies (mean of 4 plates) per IO'cells plated. To verify the leukemic nature of CFU-ALL, cells i n colonies from ALL patients were stained with Wright-Giemsa. peroxidase, and nonspecific esterase.
TGF-81 u r d TGF-82 NSSCZJ. Purified (>95%) primary leukemic blasts (2 X 10" cells/mL) were cultured, for various lengths of time. i n 35 X 10 mm Petri dishes (Falcon; Becton Dickinson) in RPM1 1640 medium (GIBCO Biocult, Paisley, UK) supplemented with 2 mmolL L-glutamine, 1 0 0 U/mL penicillin, and 2% HI-FCS i n the presence of l wmol/L quercetin. An equivalent amount of ethanol was added to cells as a control. At the end of incubation the medium was collected with siliconized pipet tips, combined with Apoprotin (final concentration, 0.04 trypsin inhibitor units/mL: Sigma), centrifuged at 8001: for 15 debris, and then stored at -80°C until use. To evaluate the concentration of TGF-p1 and TGF-p2 in conditioned medium, we used a sensitive radioimmunoassay (New England Nuclear Research products, Dupont, Boston, MA) and an immunoenzymatic method (R & D System, Minneapolis, MN) strictly specific for TGF-p1 and TGFp2 detection, respectively. Each assay was performed according to the instructions of the manufacturer. To accurately quantify TGF-p1 , 3655 samples were activated using a two-step acidificatiodneutralization method. Briefly, 100 pL samples were incubated in the presence of 10 pL 1.2 N HCl for 15 minutes at m m temperature &er vortexing. Then, 20 pL of 0.5 m o m HEPEWO.72 m o m NaOH was added to neutralize. The measured TGF-p1 value was multiplied by 1.3 to correct for the dilution. This procedure allowes the quantitation of total (active + latent) TGF-PI.
Immunohistochemical analysis. Primary leukemic blasts (2 X lo6 celldmL) were cultured for 12 hours in 35 X 10 mm Petri dishes (Falcon; Becton Dickinson) in RPM1 1640 medium supplemented with 2 mmom L-glutamine, 100 U/mL penicillin, and 2% HI-FCS at 37°C in a fully humidified 5% C02-95% air atmosphere in the presence of 1 p m o m quercetin. An equivalent amount of ethanol was added to control cells. At the end of culture, cells were incubated for 10 minutes in Caz+/MgZc-free cold PBS containing 0.02% ethylenediaminetetracetic acid, harvested by gently pipetting, and washed three times with phosphate-buffered saline (PBS) supplemented with 2 mg/mL of bovine serum albumin (Flow Labs). Cytospins prepared with Shandon Cytospin (Shandon, Cheshire, UK) were fixed with 4% para-formaldehyde in PBS for 10 minutes at room temperature (RT) and permeabilized with cold (-20T) methanol for 10 minutes. Cells were then washed with PBS and incubated for 1 hour at RT with an anti-TGF-p1 mouse monoclonal antibody (MoAb; R & D System; clone TB 21; 10 pg/mL) or with an unrelated mouse MoAb isotype-matched control. Hydrogen peroxide, normal goat blocking serum, biotinylated Igs, avidin-biotin complex, and 3-amino-9-ethylcarbazole substrate solutions were used according to the manufacturer (ABC ELITE detection system; Vector, Burlingame, CA). Cells were lightly counterstained with Mayer's hematoxylin and mounted with CrystallMount (Biomeda, Foster City, CA). In the negative controls, no immunostaining was detectable. The positivity of the reactions were independently assessed in blind fashion by two pathologists; 100 consecutive cells in three or more fields were counted. The overall intensity of the staining was arbitrarily scored as negative or positive. The results were expressed as the percentage of positively stained cells regardless of intensity.
Inhibition of TGF-p1 synthesis by antisense oligonucleotide.
The sequences of the phosphorothioate oligonucleotides were as follows: TGF-p1 antisense, 5'-CCCGGAGGGCWCGGGGGA-3'; TGF-p1 sense, 5'-TCCCCCmCGCCCTCCGGG-3'; TGFp 1 missense, 5'-GGCGAGCGAGTGAGCGCGCGG-3"4 (ATG ini- For personal use only. on September 14, 2017. by guest www.bloodjournal.org From tiation codon or its complement underlined in the sense and antisense sequences). Phosphorothioate oligonucleotides were purchased high performance liquid cbmatography (HPLQ-puriiied from MedProbe (Oslo, Norway). Cells were incubated in the presence of oligonucleotides at the final concentration of 8 pmol/L, essentially as described by others for evaluation of different genes expresion.'^^^^ Oligonucleotides or control medium were added to the cells in IMDM in the absence of ser um. Two hours later, 10% HI-FCS was added to the liquid culture. After 15 to 17 hours, oligonucleotides or control medium were added again and cells were plated as described above in a semisolid culture medium containing quercetin at various concentrations (0.001 to 10 pmol/L) or vehicle alone. Cm-Ls were scored after 6 to 10 days.
TGF-@ activity neutralizing experiments. To test the prevention of the growth inhibitory effect of quercetin by a monoclonal anti-TGF-01, $ 2 , -83 neutralizing antibody (anti-TGF-ps MoAb; Genw e ) , leukemic blasts were plated, as reported above in semisolid culture medium containing the anti-TGF-PS MoAb andor quercetin at the indicated final concentrations. Matched control cultures contained unrelated MoAb. CFU-Ls were scored after 6 to 10 days.
RESULTS

Inhibition of CFU-L by quercetin.
As shown in Table 1 , the colony formation by leukemic cells was inhibited by quercetin in all but 2 cases (patients no. 4 Secretion of TGF-p1 by leukemic blasts treated with quercetin. To ascertain whether quercetin is able to stimulate the production of TGF-B1 and TGF-p2, the amount of these cytokines were measured at various time points during 48 hours of culture in 1 &-M4 case (patient no. 10; Fig 1A) and in 1 ALL case (patient no. 16 ; Fig 1B) . A " M 4 blasts constitutively released total (active + latent) TGF-p1 that was evaluable in the medium after 24 hours of culture. In the presence of 1 pmol/L quercetin, a peak of TGF-p1 release was evident after 4 hours (Fig lA) , followed by a decrease at 12 hours to about 42% of the peak value. The concentration of TGF-B1 did not further change until the end of culture period. The cell number was stable during the culture period both in quercetin-treated and in control cultures.
ALL blasts did not show constitutive release of total (active + latent) TGF-p1 during the 48-hour period of culture. In the presence of 1 pmol/L quercetin, ALL blasts showed a peak of TGF-P1 release after 12 hours of culture (Fig lB) , followed by a decrease at 24 hours to about 50% of the peak value. The number of ALL blasts after 48 hours of culture was 80% of the initial number of cells plated both in quercetin-treated and in control cultures. The concentration of TGF-P2 was below the detection levels of the enzyme-linked immunosorbent assay (ELISA) sensitivity in all samples tested (data not shown).
Immunolocalization of TGF-PI. To determine if quercetin enhances the intracellular levels of TGF-P1 , immunohistochemical assays using an anti-TGF-Dl MoAb were performed on blasts from 1 patient with AML-M5 (patient no. tive product was localized in the cytoplasmic compartment. The blasts of the patient with AMGM5 expressed higher basal levels of TGF-P1 than the blasts of the patient with ALL. The presence of vehicle (ethanol) in the culture medium did not modify the basal level of TGF-p1 expression (data not shown). As shown in Table 2 , the percentage of blasts in leukemic bone marrow preparations was 295%.
With due caution given the low number of cells observed, it could be noted that in the remaining contaminating population (1) For 
Q concentration (PM)
preliminary dose/response curve showed that oligonucleotide concentrations greater than 10 pmol/L were toxic (data not shown). A final concentration of 8 pmol/L was used in all experiments. To show that antisense TGF-PI oligonucle&dab could inhibit quercetin-induced cytokine production, 1 case of flavonoid-sensitive ALL (ID SO% -0.4 pmolL) in which antisense TGF-P1 oligonucleotides prevented the action of quercetin (Fig 3) was analyzed for the production of TGF-P1 in the presence of TGF-P I antisense oligonucleotides. As shown in Fig 4, TGF-P1 antisense oligonucleotides could prevent the quercetin-induced cytokine production. Figure S shows the effect of TGF-P1 antisense oligonucleotide and neutralizing anti-TGF-ps MoAb on quercetindependent inhibition of leukemic blasts growth. In I AML-M4 (patient no. IO, Fig 5A) and in 1 ALL (patient no. 19, Fig SB) the addition of antisense but not sense (data not shown) or missense TGF-P1 oligonucleotides prevented the inhibitory action of quercetin. The effect of the TGF-P1 antisense oligonucleotides was proportional to the flavonoid concentrations. The prevention of quercetin effects by anti-TGF-PS MoAb was concentration dependent, resulting in a total prevention at an antibody Concentration of 100 pg/mL. In the quercetin-resistant AML-M2 case (patient no. 6, Fig  SC) , TGF-/3 1 antisense oligonucleotides produced an inhibition greater than SO% on CFU-L formation that was independent of the quercetin concentration used.
Moreover, anti-TGF-PS MoAb inhibited in a dose-dependent manner CFU-L formation, in this case with a maximum activity at 100 pg/mL anti-TGF-0s MoAb. In the quercetin-resistant AML-M1 case (patient no. 4, Fig SD) , neither TGF-P1 antisense oligonucleotides nor anti-TGF-Ps MoAb produced any evident effect on CFU-L. An isotype-matched MoAb was used Table 1 .
Results were expressed as the mean of quadruplicate cultures. Standard deviations were less than 10% and were omitted.
as a control for anti-TGF-0s MoAb; no effects on CFU-L formation was observed even at the highest concentration used (100 pg/mL; data not shown).
The addition of TCF-Pl antisense oligonucleotides prevented thc inhibitory effect of 1 pmollL quercetin in all t.he quercetin-sensitive cases (Fig 6) . The extent of the effect of TGF-P1 antisense oligonucleotides varied among the patients and did not seem to be related to the sensitivity of the leukemic blasts to quercetin.
DISCUSSION
Although originally described as a negative regulator of normal myeloid progenitor cell growth, recent studies have shown that TGF-01 is a bifunctional regulator of hematopoietic cells. TGF-P1 can either or stim~late'~.''.'~ the growth of murine and human hematopoietic progenitor cells; in particular, TGF-P1 is a potent inhibitor of primitive hematopoietic progenitors, whereas the growth of more committed progenitor cells is either not affected or stimulated by TGF-PI."' Previous studies suggested that the growth of most human leukemic cell lines and of the vast majority of cells from AML patients was inhibited by TGF-P1.'y-27 The data presented here show that the bioflavonoid quercetin inhibits the growth of AML and ALL blasts in vitro by the induction of TGF-P1 production. This finding is based on the following observations: (1) quercetin enhances the intracellular content and the secretion of TGF-01 by sensitive leukemic blasts; (2) the inhibitory action of quercetin can be partially blocked by TGF-01 antisense oligonucleotides and can be almost totally abolished by neutralizing anti-TGF-PI, $2, -03 MoAb. Because it has been reported that retinoic acid, which also induces TGF-P1 production, is able to upregulate TGF-01 receptor expression on the HL-60 cell line,33 it seems interesting to investigate whether quercetin can act in a similar fashion.
The differences between TGF-01 antisense oligonucleotides and anti-TGF-Ds MoAb in preventing the effect of quercetin could be explained as follows. (1) Neutralizing antibodies but not antisense oligonucleotides can block the effect of TGF-01 already present in quercetin untreated cells as shown by immunohistochemistry. If this is true, quercetin could stimulate the secretion in addition to the synthesis of TGF-01. (2) TGF-Pl antisense oligonucleotides are not able to completely inhibit TGF-01 synthesis, as shown in the case of the ALL presented in Fig 4. (3) The neutralizing anti-TGF-0s MoAb used in this study is able to neutralize TGF-/33 in addiction to TGF-01. It is then possible that quercetin could stimulate the release of TGF-P3 as well. TGF-02 is not involved in the quercetin-dependent growth inhibition because it is not produced by quercetin-treated leukemic blasts.
Two patients (nos. 4 and 6) behaved differently from all other patients. Particularly, in both cases leukemic blasts were resistant to the growth-inhibitory effect of quercetin. In patient no. 4, because quercetin induces TGF-P1 production in leukemic blasts (data not shown), this resistence could be dependent on the unresponsiveness of these cells to TGFDl. The growth of leukemic blasts from patient no. 6 was stimulated by TGF-@l. Actually, antisense oligonucleotides, blocking the synthesis of TGF-Pl, induced a reduction of more than 50% of the clonogenic activity in this case. Furthermore, 100 p g / d of neutralizing anti-TGF-@ MoAb inhibited almost abolished CFU-L activity (Fig 5C) . In this case, quercetin did not significantly increase the release of TGF-P1 above background (data not shown) and was unable either to stimulate or inhibit the leukemic cell growth. These data are in accordance with a recent report'' about heterogeneous responses of leukemic cell lines and primary leukemic blasts to the growth-regulatory action of TGF-@l.
Although the mechanism of the antiproliferative activity of quercetin remains to be fully clarified, there is evidence suggesting that the action of this substance is probably mediated by its interaction with the so-called type II EBS.3*6.34-36 Indeed, our data indicate that the quercetin ID 50% in sensitive leukemic cells is compatible with the dissociation constant (kd) of type I1 EBS in leukemic blasts! This possibility is also supported by the observation that the antiestrogen tamoxifene, which binds to type I1 EBS,37 induces TGF-0 1 production in estrogen-receptor-positive MCF-7 human breast cancer cells3' as well as in estrogen-receptor-negative 
